Panelists from Acepodia, Celyad and SOTIO discuss how cell therapies are impacted by the high cost of manufacturing and share their insights on ways to drive down costs.

From the back of the napkin to the bedside: Panelists from CUTISS, Humacyte and TreeFrog Therapeutics share their inspirational journeys commercializing disruptive technologies

Panelists from bluebird bio, DiscGenics and Proteus, LLC share their vision for commercial manufacturing of cell therapies.

In this article, we discuss available devices and technology developments for cell therapy products in preclinical, clinical and early commercialization phases.

Panelists from Cell Therapies, Duke University and Fate Therapeutics discuss how they envision the road ahead for some of the biggest challenges in cell therapy manufacturing.

Now it's getting serious. Panelists from bluebird bio, Juno Therapeutics and Hitachi Chemical Advanced Therapeutics Solutions (HCATS) discuss their vision for the coming era of industrialized cell therapy production.

Choosing cell therapy production equipment that is suitable for the current stage of development and will also enable smooth transfer to commercial manufacture.

Reporting from ISSCR 2018, the world's largest stem cell-focused meeting, Invetech scientist Alan Ching is reminded of the importance of this industry.

Invetech's Geoff Ball highlights dominant themes from a recent Phacilitate automation webinar on challenges of automation as the cell therapy industry matures.

Action-oriented solutions for establishing cGMP manufacture of cell and gene therapies as companies progress their development programs towards commercialization.

A visual representation highlighting challenges in cell therapy manufacturing, the benefits of automating an open process, and when to invest to maximize ROI.

In this white paper, market-leading experts from AmerisourceBergen, TrakCel and Invetech discuss what it takes to design and execute an effective commercialization strategy.